Lilly's Type 2 diabetes drug trials halted by the FDA The FDA has denied an application for approval of Type 2 diabetes drug empagliflozin, citing quality control standards at the manufacturing plant. The drug is been produced by Eli Lilly and Co and Boehringer Ingelheim. by Tabitha Laffernis